Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

9820	Companies
197077	Keywords
128165	Articles
104819	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 4 months 21 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 4 months 25 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 4 months 25 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 4 months 25 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 5 months 11 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 5 months 11 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 5 months 11 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 5 months 13 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 5 months 13 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 5 months 13 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 02/07/2026 at 01:00, 12 hours 43 minutes ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 14 hours 33 minutes ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 15 hours 42 minutes ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 22 hours 13 minutes ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 19:25, 18 hours 17 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 19 hours 50 minutes ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 17:40, 20 hours 3 minutes ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.01.26.
Published on 02/06/2026 at 16:55, 20 hours 47 minutes ago

GAC MPV Serves as Official Reception Fleet for APEC China 2026, Demonstrating the Strength of Chinese Manufacturing
Published on 02/06/2026 at 15:25, 22 hours 17 minutes ago

CES 2026 Innovation Award Honoree iGarden M1 Pro Max Launches as World's First Bionic Dual-Vision Pool Cleaner

Les Echos

Published on 02/06/2026 at 18:22, 19 hours 20 minutes ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 19 hours 20 minutes ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 21 hours 41 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 21 hours 41 minutes ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 1 day 5 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE